<!doctype html>
<html>
<head>
<meta charset="utf-8" />
<title>BioAiAssist Report</title>
<style>
  body { font-family: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, Arial; margin: 28px; color: #111; }
  h1 { margin: 0 0 8px; }
  .muted { color: #666; font-size: 12px; }
  .section { margin-top: 24px; }
  .chips { margin-top: 6px; }
  .chips .h { font-weight: 600; margin-right: 6px; }
  .chip { display: inline-block; padding: 2px 8px; border-radius: 999px; border: 1px solid #ddd; margin: 2px 4px 0 0; font-size: 12px; }
  .grid { display: grid; grid-template-columns: repeat(2, minmax(0,1fr)); gap: 16px; }
  .card { border: 1px solid #e5e7eb; border-radius: 12px; padding: 12px 14px; background: #fff; }
  table { width: 100%; border-collapse: collapse; font-size: 12.5px; }
  th, td { border: 1px solid #e5e7eb; padding: 6px 8px; vertical-align: top; }
  th { background: #f8fafc; text-align: left; }
  ul { margin: 6px 0 0 18px; }
  .kvs { display:flex; gap:12px; flex-wrap:wrap; font-size:12px; color:#333; }
  .kvs div { background:#f8fafc; padding:6px 8px; border-radius:8px; border:1px solid #e5e7eb; }
  .small { font-size: 12px; }
</style>
</head>
<body>
  <h1>BioAiAssist Report</h1>
  <div class="muted">Query: <b>what percent of mgmt methylation in gbm patients benefit from temodar</b></div>

  <div class="section">
    <div class="kvs">
      <div>Tool hits: <b>1</b></div>
      <div>Failures: <b>0</b></div>
    </div>
  </div>

  <div class="section grid">
    <div class="card">
      <h3>Slots</h3>
      
      
      <div class="chips"><span class="h">Diseases:</span> <span class="chip">glioblastoma</span></div>
      <div class="chips"><span class="h">Drugs:</span> <span class="chip">temodar</span></div>
      
      
    </div>

    <div class="card">
      <h3>Highlights</h3>
      <ul></ul>
      
    </div>
  </div>

  <div class="section card">
    <h3>Publications (top)</h3>
    <table>
      <thead><tr><th>Title</th><th>ID</th><th>Cutoff %</th><th>HR (95% CI)</th><th>Median OS (mo)</th><th>Median PFS (mo)</th></tr></thead>
      <tbody><tr>
      <td>Temozolomide-Derived Therapeutic Strategies to Overcome Resistance in Glioblastoma.</td>
      <td>PMID:40913573</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>In vitro repositioning therapy with olaparib, temozolomide and oxaliplatin in glioblastoma cell lines: U118, U87, U251, H4 and human fibroblasts.</td>
      <td>PMID:40900233</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Delactylation of H3K9 by Sirtuin6 inhibits MGMT transcription and reverses temozolomide resistance in glioblastoma.</td>
      <td>PMID:40907925</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Temozolomide-Derived AIC Is Incorporated into Purine Synthesis in Glioblastoma.</td>
      <td>PMID:40925600</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Toward Glioblastoma Treatment with High Spatiotemporal Precision: Controlling Temozolomide Release from Upconverting Nanoparticles Using Near-Infrared Light.</td>
      <td>PMID:40910700</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>A modern approach to glioblastoma using temozolomide and nanoparticles carrier drug: a standard care of combination therapy and treatment.</td>
      <td>PMID:40850359</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Polymer-engineered PROTAC nanovehicles amplify synergistic effects with temozolomide by BRD4 degradation.</td>
      <td>PMID:40726429</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Overcoming standard-of-care resistance in glioblastoma using nanoparticle-based drug delivery targeting the autophagy pathway.</td>
      <td>PMID:40912371</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Establishment of U-87MG Cellular Fibrosis as a Novel in Vitro Model to Analyze Glioblastoma Cells' Sensitivity to Temozolomide.</td>
      <td>PMID:40649899</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>SOD2-mediated TMZ-resistant Glioblastoma Cells Exhibit Cross-resistance to Irradiation.</td>
      <td>PMID:40877007</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Translational advancements in tumor vaccine therapies for glioblastomas.</td>
      <td>PMID:40933034</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Targeting TBC1D15 Reverses TMZ-resistance in Glioblastoma by Modulating Lysosomal Ca²⁺/TFEB/Cx43 Axis via Mitochondria-Lysosome Contact</td>
      <td>DOI:10.21203/rs.3.rs-7218795/v1</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Dual-action nanotherapy: Temozolomide-loaded, anti-PD-L1 scFv-functionalized lipid nanocarriers for targeted glioblastoma therapy.</td>
      <td>PMID:40914463</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Identification of &amp;lt;i&amp;gt;CXCL8, IL1A&amp;lt;/i&amp;gt;, and &amp;lt;i&amp;gt;IL1B&amp;lt;/i&amp;gt; as Hub Genes of Therapeutic Resistance in Glioblastoma Multiforme &amp;lt;i&amp;gt;via&amp;lt;/i&amp;gt; Bioinformatics Analysis.</td>
      <td>PMID:40883024</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Anti-Glioblastoma Effects of Dorzolamide Alone and in Combination with Temozolomide on U87 Cells and CD133+Glioblastoma Stem Cells.</td>
      <td>PMID:40910234</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>GPRC5A modulates resistance to temozolomide in glioblastoma through glycolytic reprogramming</td>
      <td>IND609261904</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Circadian variation in MGMT promoter methylation and expression predicts sensitivity to Temozolomide in glioblastoma</td>
      <td>DOI:10.21203/rs.3.rs-7411649/v1</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway.</td>
      <td>PMID:40802352</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>4'-Hydroxychalcone Induces Ferroptosis in Glioblastoma Through the xCT/GSH/GPX4 Axis Under the Regulation of the AKT/mTORC1/4EBP1 Pathway.</td>
      <td>PMID:40855403</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr><tr>
      <td>Melatonin Synergises the Chemotherapeutic Effect of Temozolomide in Glioblastoma by Suppressing NF-κB/COX-2 Signalling Pathways.</td>
      <td>PMID:40804775</td>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr></tbody>
    </table>
  </div>

  <div class="section card">
    <h3>Clinical Trials (top)</h3>
    <table>
      <thead><tr><th>NCT</th><th>Title</th><th>Status</th><th>Phase</th><th>Condition</th></tr></thead>
      <tbody></tbody>
    </table>
  </div>

  <div class="section card">
    <h3>Tools Run</h3>
    <table>
      <thead><tr><th>Server</th><th>Tool</th><th>OK</th><th>Elapsed (ms)</th></tr></thead>
      <tbody>
        <tr><td>europmc</td><td>search_publications</td><td>✔︎</td><td>1291</td></tr>
      </tbody>
    </table>
  </div>
</body>
</html>